Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction

Clinical Neuropharmacology

Volumn 19, Issue 6, 1996, Pages 526-531

  Oishi, M ^a   Mochizuki, Y ^a   Hara, M ^a   Yoshihashi, H ^a   Takasu, T ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Cerebral blood flow; Lacunar infarction; Sodium ozagrel

Indexed keywords

BETA THROMBOGLOBULIN; FIBRINOPEPTIDE A; OZAGREL; THROMBOCYTE FACTOR 4; THROMBOXANE A2;

ADULT; AGED; ARTICLE; BLOOD VISCOSITY; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN INFARCTION; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; DRUG EFFECT; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VASOCONSTRICTION; WHITE MATTER;

EID: 0029849509     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619060-00007     Document Type: Article

References (15)

1. Ho C, Hu H, Wong W. The serial hemostasis-related changes in patients with cerebral infarction: comparison between progressing and non-progressing stroke. Thromb Res 1989;56:635-47.
2. Kilpatrick TJ, Matkovic Z, Davis SM, McGrath CM, Dauer RJ. Hematologic abnormalities occur in both cortical and lacunar infarction. Stroke 1993;24:1945-50.
3. 2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-Y1methyl)phenyl]-2-propenoic acid (OKY-046). Jpn J Pharmacol 1986;41:393-401.
4. Naito J, Komatsu H, Ujiie A, Hamano S, Kubota T, Tsuboshima M. Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur J Pharmacol 1983;91:41-8.
5. 2 synthetase inhibitor (OKY-046) to clarify the regulation of cerebral blood flow in cerebral thrombosis. Adv Prostuglandin Thromboxane Leukotriene Res 1987;17:953-7.
6. Ohtomo E, Kutsuzawa T, Kogure K, et al. Clinical usefulness of OKY-046 on the acute stage of cerebral thrombosis - double-blind trial in comparison with placebo [Japanese]. Rinsho Iyaku 1991;7:353-88.
7. National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990;21:637-76.
8. Touho H, Karasawa J, Shishido H, Yamada K. Clinical application of stable xenon CT-CBF studies without denitrogenation. Neurol Med Chir (Tokyo) 1990;30:569-74.
9. Johnson DW, Stringer WA, Marks MP, Yonas H, Good WF, Gur D. Stable xenon CT cerebral blood flow imaging: rationale for and role in clinical decision making. AJNR 1991;12:201-13.
10. Kashiwaki S, Yamashita T, Nakano S, et al. The wash-in/washout protocol in stable xenon CT cerebral blood now studies. AJNR 1992;13:49-53.
11. Landi G, Barbarotto R, Morabito A, D'Angelo A, Mannucci PM. Prognostic significance of fibrinopeptide A in survivors of cerebral infarction. Stroke 1990;21:424-7.
12. 2: a reliable indicator of platelet hyperfunction in patients with ischemic stroke. Acta Neurol Scand 1991;83:99-102.
13. Juvela S. Cerebral infarction and release of platelet thromboxane after subarachnoid hemorrhage. Neurosurgery 1990;27:929-35.
14. 2. J Smooth Musc Res 1992;28:25-33.
15. 2 synthetase inhibitor on intracranial prostaglandins. Surg Neurol 1991;35:345-9.